A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.

NCT05338957 | Unknown Phase 1

• 1 other identifier: MRG002/HX008-C001
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 5

Brief Summary

The objective of this study is to assess the safety and tolerability of MRG002 in combination with HX008 in patients with HER2-expressed advanced malignant solid tumors; and to , explore the maximum tolerated dose (MTD), and to determine the recommended phase II dose (RP2D) of combination therapy; , and to evaluate the preliminary efficacy, pharmacokinetics, and immunogenicity of combination therapy in the targeted study population.

Conditions

Advanced Malignant Solid Tumors

Keywords

MRG002; HX008; Antibody Drug Conjugate (ADC); HER2; PD-1; Solid tumors

Outcome Measures

Primary Outcomes (3)

• Incidence of dose limiting toxicity (DLT) in each dose group

  DLT is defined as any of the treatment emergent adverse events (TEAE) as specified in the protocol that bear a definite, probable, or possible causal relationship to study drug administration within 28 days after the first dose.

  Within 28 days after the first dose.

• Adverse events

  Any reaction, side effect, or untoward event that occurs during the course of the clinical trial whether or not the event is considered related to the study drug.

  After signing informed consent until 90 days after the last dose.

• Recommended Phase II Dose (RP2D)

  The dose level of MRG002 recommended for further clinical studies based on assessment of the safety, efficacy and PK data from this study.

  Baseline to study completion (up to 24 months)

Secondary Outcomes (8)

• Objective Response Rate (ORR)

  Baseline to study completion (up to 24 months)

• Duration of Response (DOR)

  Baseline to study completion (up to 24 months)

• Disease Control Rate (DCR)

  Baseline to study completion (up to 24 months)

• Progression Free Survival (PFS)

  Baseline to study completion (up to 24 months)

• Time to Response (TTR)

  Baseline to study completion (up to 24 months)

Study Arms (1)

MRG002+HX008

EXPERIMENTAL

MRG002 will be administrated via intravenous infusion at 1.8，,2.2, or 2.6 mg/kg , (if appropriate) once on Day 1 of every 3 weeks (21-day cycle), up to 24 months. HX008 will be administrated via intravenous infusion at 3 mg/kg once on Day 1 of every 3 weeks (21-day- cycle), up to 24 months.

Drug: MRG002+HX008

Interventions

MRG002+HX008 DRUG

Administrated intravenously

MRG002+HX008

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Willing to sign the informed consent form and follow the requirements specified in the protocol.
• Aged 18 to 75 (including 18 and 75), both genders.
• Life expectancy ≥ 12 weeks.
• Patients with histopathological or cytological confirmed HER2-expressed advanced solid tumors, and with at least one measurable lesion according to the Response Criteria in Solid Tumors (RECIST v1.1).
• The score of ECOG for performance status is 0 or 1.
• The toxicity of previous anti-tumor treatment has recovered to ≤ Grade 1 as defined by NCI-CTCAEv5.0.
• No severe cardiac dysfunction.
• Organ functions must meet the basic requirements.
• Cumulative dose of anthracycline ≤ 450 mg/m2 doxorubicin or its equivalent.

You may not qualify if:

• Prior treatment with chemotherapy, biological therapy, immunotherapy, radiotherapy, investigational drugs, attenuated live vaccines, immunomodulators, CYP3A4 inhibitors/inducers, antibody-drug conjugates, etc.
• Treatment with immune checkpoint inhibitors or tumor vaccines within 60 days prior to the first dose.
• Treatment with systemic corticosteroids or other immunosuppressive drugs within 14 days prior to the first dose or during the study period.
• History of severe cardiac disease.
• Poorly controlled hypertension and hyperglycemia.
• Presence of peripheral neuropathy ≥ Grade 2.
• History of moderate or severe dyspnea at rest due to advanced malignant tumor or its complications or severe primary pulmonary disease, or current need of continuous oxygen therapy, or current interstitial lung disease or pneumonia.
• Central nervous system metastasis.
• Received major surgery within 4 weeks prior to the first dose without complete recovery.
• History of hypersensitivity to any component of MRG002 or HX008 or known history of hypersensitivity of ≥ Grade 3 to macromolecular protein products/monoclonal antibodies.
• Evidence of active infection.
• History of primary immunodeficiency or autoimmune disease.
• Female patients with a positive serum pregnancy test or who are breast-feeding or who do not agree to take adequate contraceptive measures during the treatment and for 6 months after the last dose of study treatment.
• Previous history of other primary malignancies.
• Other conditions inappropriate for participation in this study, as deemed by the investigator.

Sponsors & Collaborators

• Shanghai Miracogen Inc.: lead

Study Sites (5)

Henan Cancer Hospital

Zhengzhou, Henan, 450000, China

RECRUITING

Hunan Cancer Hospital

Changsha, Hunan, 410200, China

RECRUITING

Shandong Cancer Hospital

Jinan, Shandong, 250000, China

RECRUITING

Shanghai Oriental Hospital

Shanghai, Shanghai Municipality, 200000, China

RECRUITING

The Second Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310000, China

RECRUITING

Study Officials

• Jin Li, MD

  Shanghai Oriental Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Program Director

CONTACT

86-21-61637960; clinicaltrials@miracogen.com.cn

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 15, 2022
• First Posted: April 21, 2022
• Study Start: August 5, 2022
• Primary Completion: June 1, 2024
• Study Completion: December 1, 2024
• Last Updated: December 1, 2022

Record last verified: 2022-09

Data Sharing

• IPD Sharing: Will not share

Locations

CN (5)